Mecasermin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Mecasermin: From Severe Primary IGF-1 Deficiency to Monosomy X (Turner Syndrome)
One-Sentence Summary
Mecasermin (recombinant human IGF-1) was originally developed for severe primary IGF-1 deficiency, a condition characterized by growth hormone insensitivity. The TxGNN model predicts it may be effective for Monosomy X (Turner Syndrome), but this direction is currently supported by 0 clinical trials and 0 publications — it is a pure AI-model prediction that has not yet been independently verified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe primary IGF-1 deficiency (growth hormone insensitivity, e.g., Laron syndrome) — no formal MOA/indication record in this evidence pack |
| Predicted New Indication | Monosomy X (Turner Syndrome) |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only) |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for mecasermin in this evidence pack (flagged as a High-severity data gap). Based on the contextual information embedded in the model’s own rationale outputs, mecasermin is a recombinant human IGF-1 analogue, and its established use domain is severe primary IGF-1 deficiency — conditions marked by growth hormone insensitivity at the receptor/signaling level. This mechanistic anchor point is the basis on which TxGNN evaluates related growth-disorder phenotypes.
Monosomy X (Turner syndrome) commonly presents with short stature and a component of partial growth hormone resistance, which provides a plausible physiological rationale for IGF-1 supplementation — this is likely why it received the highest TxGNN score among the 10 candidates in this pack. Notably, a mechanistically more direct candidate also appears in this dataset at rank 3 (“growth hormone insensitivity syndrome with immune dysregulation 2”), since GH insensitivity is essentially mecasermin’s core approved use-case. However, neither candidate — including the top-ranked Monosomy X — is accompanied by any clinical trial or literature evidence in this pack.
Given the complete absence of supporting clinical or literature evidence, this prediction should be treated as a hypothesis-generating signal only. An independent search for any existing off-label use of IGF-1 in Turner syndrome (a population that already sometimes receives growth hormone therapy) is needed before this candidate can be meaningfully advanced.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No EU marketing authorizations are recorded for mecasermin in this evidence pack (market status: Not marketed, 0 total licenses). No product/authorization table can be generated at this time.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: key warnings, contraindications, and drug interaction data are currently unavailable in this evidence pack. Retrieval of TFDA/EMA label warnings and contraindications is flagged as a blocking data gap for any safety review.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported only by a TxGNN model score (Evidence Level L5), with zero clinical trials and zero publications identified. In addition, the drug is not currently marketed in the EU, and mechanism-of-action and safety label data are both missing — including a blocking-severity gap on warnings/contraindications. There is insufficient evidence to move beyond model prediction at this stage.
To proceed, the following is needed:
- Retrieve TFDA/EMA label warnings and contraindications for mecasermin (blocking gap — required before any safety screening can begin)
- Retrieve formal mechanism-of-action documentation from DrugBank or equivalent source (high-severity gap)
- Conduct an independent literature/registry search for off-label IGF-1 use in Turner syndrome, since this pack contains no such evidence
- Re-evaluate the mechanistically closer candidate (growth hormone insensitivity syndrome, rank 3) in parallel, as it aligns more directly with mecasermin’s known pharmacology
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.